ストックスクリーナーアプリを入手
7.2476
3.22%
0.2576
Verastem Inc (VSTM) 最新ニュース
It would be worthwhile to take a closer look at Verastem Inc (VSTM) - uspostnews.com
Analyze Verastem Inc (NASDAQ: VSTM) Before Investing. - Stocksregister
Verastem, Inc. (NASDAQ:VSTM) Shares Bought by Geode Capital Management LLC - Defense World
Verastem Oncology rises on $75M private placement - MSN
Verastem Oncology secures $75 million in private placement By Investing.com - Investing.com India
Verastem Inc [VSTM] Shares Rise 5.34 % on Thursday - knoxdaily.com
Merck cuts several Phase 2 programs; Vyne’s Phase 1b psoriasis trial put on clinical hold - Endpoints News
Verastem Shares Rise After Agreement to Sell Securities Worth Roughly $75 Million - marketscreener.com
Verastem Announces $75M Private Placement Agreement - TipRanks
Verastem Oncology Announces $75 million Private Placement | VSTM Stock News - GuruFocus
Verastem Oncology Announces $75 million Private Placement - Bluefield Daily Telegraph
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge - ADVFN
12-Month Price Target For Verastem Inc (NASDAQ:VSTM) Now Sits At 14 - Marketing Sentinel
Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors - BioSpace
Verastem (VSTM) Gains FDA Nod for Novel Cancer Drug VS-7375 - GuruFocus
Verastem (VSTM) Advances VS-7375 for Cancer Treatment with FDA A - GuruFocus
Verastem Oncology to initiate trial for its targeted cancer therapy (VSTM:NASDAQ) - Seeking Alpha
Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral - GuruFocus
FDA clears Verastem’s new drug for clinical trial By Investing.com - Investing.com Canada
There is no way Verastem Inc (VSTM) can keep these numbers up - Sete News
(VSTM) Trading Report - news.stocktradersdaily.com
Verastem Oncology to Report Q1 Earnings: What's in the Cards? - MSN
Verastem Inc (VSTM) rating initates by Jefferies - knoxdaily.com
Was there any good news for Verastem Inc (VSTM) stock in the last session? - uspostnews.com
Verastem (NASDAQ:VSTM) Stock Rating Lowered by StockNews.com - Defense World
Top Cancer Stocks to Buy to Boost Your Portfolio's Health - Yahoo Finance
Verastem, Inc. (NASDAQ:VSTM) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Jefferies Initiates Coverage of Verastem (LSE:0LOV) with Buy Recommendation - Nasdaq
Verastem (VSTM): Jefferies Initiates Coverage with Buy Rating Am - GuruFocus
Verastem: RAMP-203 Study Could Be Next Big Win For Avutometinib Combination (NASDAQ:VSTM) - Seeking Alpha
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Jefferies Initiates Verastem at Buy With $15 Price Target - marketscreener.com
Jefferies Initiates Coverage of Verastem (VSTM) with Buy Recommendation - Nasdaq
Verastem stock initiated Buy at Jefferies (VSTM:NASDAQ) - Seeking Alpha
Verastem (VSTM) Receives Buy Rating from Jefferies with Promisin - GuruFocus
Jefferies sets $15 price target on Verastem stock with Buy rating - Investing.com Canada
Verastem (NASDAQ:VSTM) Share Price Crosses Above 200-Day Moving Average – What’s Next? - Defense World
Mizuho Securities Adjusts Verastem Price Target to $8 From $9, Maintains Outperform Rating - marketscreener.com
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Verastem Oncology's Strategic Move: 247K Share Package Ties New Talent to Sales Goals - Stock Titan
Where are the Opportunities in (VSTM) - news.stocktradersdaily.com
Verastem Oncology Reports Progress in Cancer Treatments - TipRanks
Verastem, Inc. (NASDAQ:VSTM) Short Interest Update - Defense World
Verastem (NASDAQ:VSTM) Upgraded at StockNews.com - MarketBeat
Bank of New York Mellon Corp Has $457,000 Stake in Verastem, Inc. (NASDAQ:VSTM) - Defense World
Wall Street Analysts Believe Verastem (VSTM) Could Rally 100.94%: Here's is How to Trade - Yahoo Finance
(VSTM) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025 - Business Wire
Verastem CFO Daniel Calkins sells shares worth $630 - Investing.com India
Verastem CFO Daniel Calkins sells shares worth $630 By Investing.com - Investing.com Australia
H.C. Wainwright lifts Verastem stock price target to $10 By Investing.com - Investing.com Canada
Guggenheim lifts Verastem stock target to $14, maintains buy By Investing.com - Investing.com Canada
H.C. Wainwright lifts Verastem stock price target to $10 - Investing.com India
Royal Bank of Canada Lowers Verastem (NASDAQ:VSTM) Price Target to $14.00 - Defense World
RBC Cuts Price Target on Verastem to $14 From $16, Maintains Outperform Rating -March 21, 2025 at 08:40 am EDT - Marketscreener.com
1.36%
0.60%
大文字化:
|
ボリューム (24 時間):